Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR 181946 C>T

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

EGFR exon 19 deletion (79)

EGFR amplification (52)

EGFR exon 18 deletion (3)

EGFR exon 2-7 deletion + EGFR amplification (2)

EGFR amplification + ERBB2 amplification (1)

EGFR exon 19 deletion + HER-2 amplification (1)

EGFR exon 21 deletion (1)

EGFR T790M + exon 19 deletion (0)

EGFR amplifcation (0)

EGFR exon 19 deletion (79)

EGFR amplification (52)

EGFR exon 18 deletion (3)

EGFR exon 2-7 deletion + EGFR amplification (2)

EGFR amplification + ERBB2 amplification (1)

EGFR exon 19 deletion + HER-2 amplification (1)

EGFR exon 21 deletion (1)

EGFR T790M + exon 19 deletion (0)

EGFR amplifcation (0)

›

almost2years

Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma. (PubMed, Dose Response)

Genetic factors did not have a direct impact on pain management but had a significant effect on the response to TKIs leading to pain alleviation. EGFR mutation subtype and the EGFR 181946 C>T SNP had a significant effect on the response to TKI inducing an indirect anti-dolorous effect.

almost 2 years ago

Journal

|

EGFR (Epidermal growth factor receptor)

|

EGFR mutation • EGFR 181946 C>T